Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kyntra BioMEX:KYNB 34 FCF Margin % is -371.51% as of Mar. 2026. GuruFocus rates MEX:KYNB with a GF Score™ of 34/100 and a GF Value™ of MXN104.15 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 952 Biotechnology companies, Kyntra Bio ranks worse than 64.18% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Kyntra Bio's Free Cash Flow for the
three
months ended in Mar. 2026 was MXN-250.4 Mil. Kyntra Bio's Revenue for the
three
months ended in Mar. 2026 was MXN67.4 Mil. Therefore, Kyntra Bio's FCF Margin % for the quarter that ended in Mar. 2026 was -371.51%.
The historical data trend for Kyntra Bio's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:KYNB vs ACTU, PLRZ, IGC: FCF Margin % Comparison
For the Biotechnology subindustry, Kyntra Bio's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyntra Bio FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kyntra Bio's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Kyntra Bio's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kyntra Bio (MEX:KYNB) has a FCF Margin % of -371.51% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Kyntra Bio and its competitors. According to the industry distribution chart, Kyntra Bio ranks #611 out of 952 companies in the Biotechnology industry, placing it in the top 64.2%.
Is Kyntra Bio's FCF Margin % too high?
Kyntra Bio's current FCF Margin % is -371.51%. Based on the distribution chart, Kyntra Bio ranks #611 out of 952 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Kyntra Bio has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kyntra Bio's FCF Margin % compare to ACTU and PLRZ?
According to the Biotechnology industry distribution chart, Kyntra Bio ranks #611 out of 952 companies for FCF Margin %. This places Kyntra Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Kyntra Bio and its competitors. Kyntra Bio's current FCF Margin % is -371.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyntra Bio stock overvalued right now?
Based on GuruFocus' analysis, Kyntra Bio (MEX:KYNB) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN104.15, compared to a current price of MXN127.90 — trading 22.8% above its estimated fair value. The current FCF Margin % is -371.51%. Kyntra Bio's overall GF Score™ is 34/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Kyntra Bio (MEX:KYNB), the current FCF Margin % is -371.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyntra Bio (MEX:KYNB) Overvalued in 2026?
Based on GuruFocus' analysis, Kyntra Bio stock appears to be overvalued.
The current stock price of MXN127.90 is trading 22.8% above its estimated GF Value™ of MXN104.15.
GuruFocus considers Kyntra Bio to be Significantly Overvalued.
Key valuation signals for MEX:KYNB:
FCF Margin %: -371.51%
GF Value™: MXN104.15 vs. price of MXN127.90 (22.8% above fair value)
No single metric tells the full story. See the MEX:KYNB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
34GF Score
Get the complete analysis for MEX:KYNB
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:KYNB has been successfully added to your 
